Ionis Pharmaceuticals, Inc. Common Stock

Day range

$42.63 – $43.80

Open

$43.80

Prev close

$43.91

Volume

745.51K

Market cap

$7.3B

Shares out

166.18M

P/E

—

P/S

8.35

P/B

16.59

P/FCF

—

ROE

-128.5%

ROA

-18.9%

Debt/Equity

3.01

Div yield

0.00%

As of Oct 22, 2026

• Deal agreementsOct 21, 2026

  GSK licensed bepirovirsen from Ionis in 2019 under a collaborative development and licensing agreement. Under the terms of the agreement, Ionis has received an upfront payment, license fee and development and regulatory milestone payments and is eligible to receive additional regulatory and sales milestone payments as well as tiered royalties of 10-12% on net sales of bepirovirsen.

• Deal agreementsSep 23, 2026

  Roche licensed sefaxersen from Ionis for the treatment of complement-mediated diseases. Under the terms of the agreement, Ionis received an upfront payment, license fee and development milestone payments and is eligible to receive regulatory and sales milestone payments as well as tiered royalties on net sales of sefaxersen.

• Material agreementsSep 4, 2026

  In June 2026, Ionis entered into a license agreement with Recordati, a global pharmaceutical company headquartered in Italy, focused on specialty and rare diseases, under which Recordati obtained exclusive rights to develop and commercialize zilganersen in all countries outside the U.S.

• Business developmentsSep 4, 2026

  Ionis announced that its partner, Novartis, reported that the pelacarsen Phase 3 Lp(a)HORIZON study ... did not meet its primary endpoint of reducing the risk of cardiovascular events ... compared to placebo. ... Pelacarsen demonstrated an acceptable safety profile.

• Earnings and performanceJul 29, 2026

  On July 29, 2026, Ionis Pharmaceuticals, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended June 30, 2026. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects.

Days to cover

4.6

Short interest

22.51M

Avg volume

4.88M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
  positiveThe Motley Fool· Oct 21, 2026
• NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
  positiveZacks Investment Research· Oct 8, 2026
• Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
  positiveZacks Investment Research· Oct 5, 2026
• Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
  positiveThe Motley Fool· Oct 1, 2026
• 18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
  positiveThe Motley Fool· Sep 28, 2026